- $725.62m
- $415.92m
- $14.02m
Annual balance sheet for Immunome, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 2.54 | 39.8 | 49.2 | 20.3 | 138 |
| Net Total Receivables | — | — | — | 0.847 | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 3.12 | 42.9 | 56.6 | 22.6 | 145 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.7 | 1.53 | 0.855 | 0.965 | 3.64 |
| Other Long Term Assets | |||||
| Total Assets | 5.06 | 44.5 | 57.9 | 24 | 149 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.67 | 3.04 | 9.73 | 7.33 | 21.8 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 1.8 | 3.18 | 9.74 | 7.39 | 28.7 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 3.26 | 41.3 | 48.2 | 16.7 | 120 |
| Total Liabilities & Shareholders' Equity | 5.06 | 44.5 | 57.9 | 24 | 149 |
| Total Common Shares Outstanding |